Repositioning Candidate Details
| Candidate ID: | R0796 |
| Source ID: | DB05431 |
| Source Type: | investigational |
| Compound Type: | small molecule |
| Compound Name: | MLN-977 |
| Synonyms: | -- |
| Molecular Formula: | C16H19FN2O4 |
| SMILES: | NC(=O)N(O)CCC#C[C@@H]1CC[C@@H](COC2=CC=C(F)C=C2)O1 |
| Structure: |
|
| DrugBank Description: | MLN-977 is a small molecule compound that inhibits the production of leukotrienes, especially 5-lipoxygenase. It is developed by PharmaEngine to treat asthma and chronic obstructive pulmonary disease. |
| CAS Number: | 175212-04-1 |
| Molecular Weight: | 322.336 |
| DrugBank Indication: | Investigated for use/treatment in asthma and chronic obstructive pulmonary disease (COPD). |
| DrugBank Pharmacology: | -- |
| DrugBank MoA: | MLN977 is a second generation compound in the class of asthma therapies known as 5-LO inhibitors, which block the production of leukotrienes. Leukotrienes are major mediators of the inflammatory response. |
| Targets: | Arachidonate 5-lipoxygenase |
| Inclusion Criteria: | Therapeutic strategy associated |
| Strategy ID | Strategy | Synonyms | Related Targets | Related Drugs | |
|---|---|---|---|---|---|
| S05 | Anti-inflammatory | inflammatory | Bile acid; TNF-a inhibitor; Dual PPAR-α and -δ agonists; Toll-Like Receptor; (TLR)-4 antagonist; Caspase inhibitor; ASK-1 inhibitor | Ursodeoxycholic Acid; Pentoxifylline; Elafibranor; JKB-121; Emricasan; Selonsertib; | Details |
| Target ID | Target Name | GENE | Action | Class | UniProtKB ID | Entry Name |
|---|
| Diseases ID | DO ID | Disease Name | Definition | Class |
|---|